Welcome to our dedicated page for CELLECTAR BIOSC news (Ticker: CLRBZ), a resource for investors and traders seeking the latest updates and insights on CELLECTAR BIOSC stock.
The CLRBZ news page aggregates recent disclosures and media coverage related to Cellectar Biosciences, Inc., a late-stage clinical radiopharmaceutical and biotechnology company listed on NASDAQ under the symbol CLRB. Company communications describe Cellectar as focused on developing phospholipid-based targeted radiotherapeutics and radioconjugates for the treatment of cancer.
News items associated with CLRBZ and Cellectar typically cover updates on the company’s lead asset iopofosine I 131, an iodine-131 Phospholipid Drug Conjugate designed for hematologic and solid tumor cancers, as well as pipeline programs such as CLR 121125 (CLR 125), an iodine-125 Auger-emitting candidate for solid tumors, and CLR 121225 (CLR 225), an actinium-225 based candidate for pancreatic and other cancers. Coverage often includes clinical trial milestones, such as Phase 2b and Phase 1b study updates in Waldenstrom’s macroglobulinemia and pediatric high-grade glioma, and early-stage development plans in triple-negative breast cancer and pancreatic ductal adenocarcinoma.
Investors and observers can use this news feed to follow regulatory developments described by the company, including FDA designations like Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease, and Fast Track, as well as EMA PRIME and orphan designations. Announcements may also highlight guidance from the European Medicines Agency’s Scientific Advice Working Party on potential Conditional Marketing Authorization pathways, along with information on isotope supply agreements and clinical research partnerships.
By reviewing the CLRBZ news page, readers can track how Cellectar characterizes progress across its PDC-based radiotherapeutic pipeline, including scientific presentations, preclinical data releases, financing transactions, and collaboration agreements that the company reports as supporting its oncology programs.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on cancer treatment, has scheduled its third quarter 2024 financial results announcement and corporate update for November 18, 2024, at 8:30 a.m. ET. The company will host a conference call accessible via toll-free number 1-800-717-1738 with conference ID 80659, and a webcast will be available. A replay of the call will be accessible through the company's investor relations website.